Drug Profile


Alternative Names: ENA 713; ENA 713D; Exelon; Exelon Patch; Exelon TDS; ONO-2540; Prometax; Rivastach Patch; Rivastigmine transdermal system; SDZ 212713; SDZ ENA 713

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Ono Pharmaceutical
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Dementia
  • Phase III Delirium

Most Recent Events

  • 01 Feb 2016 Novartis completes a phase III trial in Delirium (In the elderly) in France (NCT01487317)
  • 04 Sep 2015 First Generic equivalent of Exelon® Patch available in USA for Alzheimer's disease
  • 24 Aug 2015 Ono Pharmaceuticals receives approval for a one-step titration regimen for Alzheimer's disease in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top